Table 4.
Signal scores for JAK inhibitors-associated embolic and thrombotic events, venous (SMQ)
| JAK inhibitor | Total (n) | Cases (n) | ROR (95% CI) | IC (95% CI) |
|---|---|---|---|---|
| JAK inhibitors | 6631 | 115 | 1.57* (1.30–1.89) | 0.63 (− 0.0001 to 1.25) |
| Tofacitinib | 2431 | 49 | 1.82* (1.37–2.42) | 0.83 (− 0.13 to 1.78) |
| Ruxolitinib | 1513 | 15 | 0.89 (0.53–1.47) | − 0.16 (− 1.84 to 1.51) |
| Baricitinib | 1338 | 32 | 2.17* (1.53–3.08) | 1.05 (− 0.13 to 2.22) |
| Peficitinib | 651 | 5 | 0.68 (0.28–1.65) | − 0.47 (− 3.19 to 2.26) |
| Upadacitinib | 580 | 12 | 1.87* (1.05–3.31) | 0.79 (− 1.07 to 2.66) |
| Filgotinib | 233 | 3 | 1.15 (0.37–3.60) | 0.14 (− 3.21 to 3.50) |
| Abrocitinib | 30 | 0 | – | − |
JAK janus kinase, SMQ Standardised Medical Dictionary for Regulatory Activities Query, ROR reported odds ratio, IC information component
*The adverse events are detected as signals